Title:
CANCER TREATMENT BY COMBINED USE OF IMMUNE CHECKPOINT REGULATOR AND LOW-MOLECULAR-WEIGHT COMPOUND HAVING ANTI-FIBROTIC EFFECT
Document Type and Number:
WIPO Patent Application WO/2024/048478
Kind Code:
A1
Abstract:
Disclosed is a novel treatment method in which the effectiveness of cancer treatment is improved by using an immune checkpoint regulator in combination. An anticancer drug according to the present invention has, as an active ingredient, a compound that is N-(4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-3-yl)-3-(piperidine-1-yl)benzamide, a pharmacologically acceptable salt thereof, or a solvate of said compound or said salt, the anticancer drug being used in combination with at least one immune checkpoint regulator. The immune checkpoint regulator is, e.g., an immune checkpoint inhibitor such as an antagonistic anti-PD-1 antibody.
Inventors:
MATSUSHIMA KOUJI (JP)
UEHA SATOSHI (JP)
YOKOCHI SHOJI (JP)
ISHIWATA YOSHIRO (JP)
UEHA SATOSHI (JP)
YOKOCHI SHOJI (JP)
ISHIWATA YOSHIRO (JP)
Application Number:
PCT/JP2023/030844
Publication Date:
March 07, 2024
Filing Date:
August 28, 2023
Export Citation:
Assignee:
UNIV TOKYO SCIENCE FOUND (JP)
CHEMOKINE FRONTIER INC (JP)
CHEMOKINE FRONTIER INC (JP)
International Classes:
A61K31/454; A61K39/395; A61K45/00; A61P35/00; A61P43/00
Domestic Patent References:
| WO2014003124A1 | 2014-01-03 |
Other References:
MELISI DAVIDE, OH DO-YOUN, HOLLEBECQUE ANTOINE, CALVO EMILIANO, VARGHESE ANNA, BORAZANCI ERKUT, MACARULLA TERESA, MERZ VALERIA, ZE: "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL, LONDON, GB, vol. 9, no. 3, 1 March 2021 (2021-03-01), GB , pages e002068, XP093144891, ISSN: 2051-1426, DOI: 10.1136/jitc-2020-002068
上羽悟史. 抗CD4抗体と抗PD-1/PD-L1抗体の併用によるがん免疫療法. 日本リンパ網内系学会会誌. 2016, 第56回日本リンパ網内系学会総会・予稿集, p. 60, シンポジウム2 免疫系の制御によるがん治療の進歩 SY2-2, (The journal of the Japanese Society of Lymphoreticular Tissue research), non-official translation (UEHA, Satoshi. Cancer Immunotherapy Based on Combined Use of Anti-CD 4 Antibody and Anti-PD-1/PD-L1 Antibody. Proceedings of the 56th Meeting of the Japanese Society of Lymphoreticular Tissue Research. Symposium 2: Progress in Cancer Treatment Based on Immune System Regulation.)
上羽悟史. 抗CD4抗体と抗PD-1/PD-L1抗体の併用によるがん免疫療法. 日本リンパ網内系学会会誌. 2016, 第56回日本リンパ網内系学会総会・予稿集, p. 60, シンポジウム2 免疫系の制御によるがん治療の進歩 SY2-2, (The journal of the Japanese Society of Lymphoreticular Tissue research), non-official translation (UEHA, Satoshi. Cancer Immunotherapy Based on Combined Use of Anti-CD 4 Antibody and Anti-PD-1/PD-L1 Antibody. Proceedings of the 56th Meeting of the Japanese Society of Lymphoreticular Tissue Research. Symposium 2: Progress in Cancer Treatment Based on Immune System Regulation.)
Attorney, Agent or Firm:
TANIGAWA AND PARTNERS, PATENT FIRM (JP)
Download PDF: